C

Carmell Corp
NASDAQ:CTCX

Watchlist Manager
Carmell Corp
NASDAQ:CTCX
Watchlist
Price: 0.1973 USD 1.39%
Market Cap: 5.9m USD

Relative Value

There is not enough data to reliably calculate the relative value of CTCX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTCX Relative Value
Base Case
Not Available
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
11
Median 3Y
20.1
Median 5Y
0
Industry
7.9
vs History
vs Industry
8
Median 3Y
-0.3
Median 5Y
-0.9
Industry
24
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-14.1
Industry
21.6
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-12
Industry
23.7
vs History
vs Industry
68
Median 3Y
-1.5
Median 5Y
1.9
Industry
3.4
vs History
14
vs Industry
11
Median 3Y
19.9
Median 5Y
0
Industry
8.3
vs History
14
vs Industry
7
Median 3Y
21.5
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-19.4
Industry
6.7
vs History
vs Industry
Median 3Y
-5
Median 5Y
-19.1
Industry
7.2
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-14
Industry
8.2
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-13.9
Industry
6.7
vs History
vs Industry
69
Median 3Y
0.6
Median 5Y
1.9
Industry
5.7

Multiples Across Competitors

CTCX Competitors Multiples
Carmell Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Carmell Corp
NASDAQ:CTCX
5.9m USD 181.2 -0.2 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
393.4B USD 6.6 167.3 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
171.4B USD 4.8 24.5 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
153.3B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.9B USD 9.7 31 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
45.8B EUR 14.9 35.1 60.7 62.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD 16.5 1 217.1 159.9 193.9
P/S Multiple
Revenue Growth P/S to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average P/S: 3 072 397.2
181.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14.9
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.5
46%
0.4
P/E Multiple
Earnings Growth PEG
US
C
Carmell Corp
NASDAQ:CTCX
Average P/E: 191.3
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.5
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.1
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 217.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBITDA: 39.9
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
60.7
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBIT: 46.1
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
193.9
N/A N/A